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ABSTRACT
Objective Primary sclerosing cholangitis (PSC) is in 
70% of cases associated with inflammatory bowel 
disease. The hypermorphic T108M variant of the orphan 
G protein- coupled receptor GPR35 increases risk for 
PSC and ulcerative colitis (UC), conditions strongly 
predisposing for inflammation- associated liver and 
colon cancer. Lack of GPR35 reduces tumour numbers 
in mouse models of spontaneous and colitis associated 
cancer. The tumour microenvironment substantially 
determines tumour growth, and tumour- associated 
macrophages are crucial for neovascularisation. We aim 
to understand the role of the GPR35 pathway in the 
tumour microenvironment of spontaneous and colitis- 
associated colon cancers.
Design Mice lacking GPR35 on their macrophages 
underwent models of spontaneous colon cancer or 
colitis- associated cancer. The role of tumour- associated 
macrophages was then assessed in biochemical and 
functional assays.
Results Here, we show that GPR35 on macrophages 
is a potent amplifier of tumour growth by stimulating 
neoangiogenesis and tumour tissue remodelling. 
Deletion of Gpr35 in macrophages profoundly reduces 
tumour growth in inflammation- associated and 
spontaneous tumour models caused by mutant tumour 
suppressor adenomatous polyposis coli. Neoangiogenesis 
and matrix metalloproteinase activity is promoted by 
GPR35 via Na/K- ATPase- dependent ion pumping and 
Src activation, and is selectively inhibited by a GPR35- 
specific pepducin. Supernatants from human inducible- 
pluripotent- stem- cell derived macrophages carrying the 
UC and PSC risk variant stimulate tube formation by 
enhancing the release of angiogenic factors.
Conclusions Activation of the GPR35 pathway 
promotes tumour growth via two separate routes, by 
directly augmenting proliferation in epithelial cells that 
express the receptor, and by coordinating macrophages’ 
ability to create a tumour- permissive environment.
INTRODUCTION
Colorectal cancer (CRC) is the leading cause of 
death from gastrointestinal malignancy, and the 
second most common cause of cancer- related 
death in the western world.1 Mutations in the 
adenomatous polyposis coli (APC) gene are a key 
event in both spontaneous and hereditary CRC.2 
A subset of CRC is due to intestinal inflammation, 
referred to as colitis- associated cancer (CAC).3 CAC 
typically arises from long- standing ulcerative colitis 
(UC), and is particularly frequent in a variant of 
UC (often referred to as PSC- inflammatory bowel 
disease (IBD)) that is often present in patients with 
primary sclerosing cholangitis (PSC). PSC and UC 
are chronic inflammatory conditions of the bile 
ducts and the large intestine, respectively.4 5 Both 
diseases have an extreme cumulative risk for the 
development of cancer.6 7
A coding variant in GPR35 (rs3749171, leading 
to a T108M substitution) is associated with risk for 
PSC and UC.8 9 GPR35 is an orphan G protein- 
coupled receptor that interacts with the sodium- 
potassium pump (Na/K- ATPase).10 Na/K- ATPase 
is the quintessential controller of a cell’s electro-
chemical gradient, for which ~30% of cellular 
energy in the form of ATP is expended. The GPR35 
interaction promotes Na/K- ATPase’s pump func-
tion, secondarily controlling Ca2+ homoeostasis. 
The UC/PSC- associated GPR35T108M variant is 
hypermorphic in its stimulatory activity on the 
pump.10 Na/K- ATPase acts as a scaffold for the 
non- receptor tyrosine kinase Src, and modulates 
Significance of this study
What is already known on this subject?
 ► A coding variant (T108M) in the G protein- 
coupled receptor GPR35 increases the risk 
for primary sclerosing cholangitis (PSC) and 
ulcerative colitis (UC). PSC and UC are chronic 
inflammatory conditions that significantly 
increase the risk for the development of cancer, 
and GPR35 is highly expressed in colorectal 
cancer.
 ► GPR35 interacts with the sodium- potassium 
pump (Na/K- ATPase). Na/K- ATPase is 
the quintessential controller of a cell’s 
electrochemical gradient and controls Src- 
kinase signalling. The UC/PSC- associated 
GPR35T108M is hypermorphic and promotes the 
pump’s ion exchange and signal transduction 
function resulting in increased proliferation of 
intestinal epithelial cells. Mice lacking Gpr35 
globally or conditionally in their Vln+ cells 
(intestinal epithelial cells) develop reduced 
numbers of tumours in sporadic cancer and 
colitis- associated cancer.
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its phosphorylation.11 GPR35, via its Na/K- ATPase interaction, 
regulates the proliferation of intestinal epithelial cells by phos-
phorylation and activation of Src.10 Indeed mice lacking Gpr35 
develop fewer tumours in a sporadic murine cancer model (in 
mice carrying an Apcmin allele) and in a model of CAC induced 
by the mutagen azoxymethane followed by dextran sodium 
sulphate (AOM- DSS).10 GRP35 is known to be highly expressed 
in human CRC12 13 and deletion of Gpr35 selectively in the intes-
tinal epithelium was sufficient to reduce tumour numbers.10 Kaya 
et al report that LPA activation of GPR35 in CX3CR1+mac-
rophages maintains tumour necrosis factor- mediated intestinal 
homoeostasis and thereby reduces acute inflammation.14
Mutations in oncogenes and tumour- suppressor genes lead to 
unorganised proliferation and reduced cell death which initiates 
the development of malignancies. Tumour growth is not only 
determined by signal transduction pathways leading to prolif-
eration,15 but also by neoangiogenesis.16 The tumour micro-
environment (TME) consists of several cell types including 
leukocytes,17 18 as well as the extracellular matrix, which are all 
important for growth and progression of tumours.19 Tumour 
cells themselves have the capability to recruit cells of the TME 
by releasing chemokines, cytokines and proteinases.20 This coop-
eration between cells of the TME and malignant cells leads to 
tissue remodelling and angiogenesis within the tumour, resulting 
in enhanced proliferation and metastatic capability.21
Atypical angiogenesis does not only play an important role in 
tumour neo- vascularisation,22 but is also a hallmark of chronic 
inflammation including IBD.23 Release of CXCL-1 (KC, GROα) 
and/or CXCL-8 (interleukin 8, IL-8) together with VEGF initiate 
tumour angiogenesis and lead to tumour growth by guaran-
teeing sufficient supply of nutrients.24 These cytokines are also 
increased in IBD and augment neovascularisation in areas of 
tissue regeneration.23 Tumour- associated macrophages (TAMs) 
as part of the TME can resemble either proinflammatory M1 
macrophages or M2- like macrophages with immunosuppres-
sive and tumour- promoting properties.18 25 Increased numbers 
of TAMs, in particular M2- like cells, directly correlate with 
poor prognosis of cancer by stimulating angiogenesis, modu-
lating tumour cell invasion, cell motility as well as persistent 
growth.26–28 TAMs also express proteinases including matrix 
metalloproteinases (MMPs), which play a key role in angiogen-
esis and progression of tumours.29 Neutrophils have also been 
demonstrated to contribute to tumour angiogenesis employing 
similar mechanisms.30
Here, we report that macrophage GPR35 is important in 
vessel growth in healthy and malignant tissue. GPR35 critically 
controls the size of intestinal tumours in murine spontaneous 
(APCmin) and CAC (AOM/DSS) models. We demonstrate that 
deletion of Gpr35 in macrophages recapitulates the profoundly 
reduced tumour size observed in Gpr35–/– germline mutant 
mice, identifying macrophage GPR35 as a key driver of tumour 
growth. Aortic tissue from mice lacking GPR35 is strikingly 
less capable of developing vascular sprouts. Vessel sprouting 
is mainly dependent on GPR35’s interaction with the Na/K- -
ATPase- dependent activation of Src kinase, and does not require 
ligand- induced GPR35 activation.
MATERIALS AND METHODS
For detailed resources, please see online supplemental materials 
and methods and online supplemental table 1.
RESULTS
Macrophage GPR35 promotes tumour growth
We had previously reported a reduced incidence of intestinal 
tumours in Gpr35–/– mice in spontaneous CRC (Apcmin) and CAC 
(AOM/DSS) models.10 Selective deletion of Gpr35 in the intes-
tinal epithelium (ie, in Gpr35fl/fl;Vil- Cre or ‘Gpr35ΔIEC’ mice) 
was sufficient to reduce tumour incidence in both models.10 In 
both CRC and CAC, individual tumours in Gpr35–/– mice were 
strikingly smaller compared with Gpr35+/+ tumours (figure 1A). 
Levels of CXCL-1, VEGF and IL-1β, proangiogenic mediators 
mainly produced by TAM,28 31 32 were substantially lower in 
Gpr35–/– compared with Gpr35+/+ tumours (figure 1B). This 
prompted us to ask whether GPR35 on LysM+ cells, which 
encompasses macrophages and neutrophils,33 might mediate a 
TME pathway that promotes tumour growth.17 18 We, therefore, 
generated Apcmin allele- carrying mice with LysM- specific Gpr35 
deletion (Gpr35fl/fl;LysM-Cre;Apcmin/+, ‘Gpr35ΔMΦ;Apcmin’) and 
compared them to their Gpr35- sufficient controls (Gpr35fl/
fl;Apcmin/+, ‘Gpr35fl/fl;Apcmin’) (figure 1E). Gpr35ΔMΦ;Apcmin mice 
developed tumours more than three times smaller than Gpr35fl/
fl;Apcmin mice (figure 1F), although the total number of tumours 
was not significantly different (figure 1C). Subjecting Gpr35ΔMΦ 
(ie, without an Apcmin allele) to AOM/DSS colitis revealed a 
similarly stark reduction in tumour size compared with their 
Gpr35fl/fl controls (figure 1F). In this model of CAC, even the 
total tumour count in Gpr35ΔMΦ mice was half of that in Gpr35fl/
fl mice (figure 1D), and associated with a higher survival rate 
(online supplemental figure 1D). The reduced incidence and size 
of tumours in Gpr35ΔMΦ mice was not linked to protection from 
DSS- induced colitis, as weight loss during short- term (ie, 7 days) 
Significance of this study
What are the new findings?
 ► Tumours lacking GPR35 are smaller compared with wild- type 
tumours. Deletion of Gpr35 in LysM+ cells reduces tumour 
growth substantially. GPR35 on macrophages increases 
the secretion of the angiogenic factors CXCL-1 (the murine 
orthologue of interleukin 8 (IL-8)) and VEGF. GPR35 on 
LysM+ cells promotes vessel sprouting from ex vivo cultured 
aortic rings which is dependent on its interaction with the 
Na/K- ATPase. Loss of GPR35 on macrophages reduces matrix 
metalloproteinase activity in tumour tissue, a prerequisite for 
tissue remodelling and angiogenesis. Macrophages carrying 
the human risk variant GPR35T108M secrete substantially 
more VEGF, IL-8 and matrix- metallo- proteinases (MMP2). 
Risk variant supernatants induce tube formation in human 
microvascular endothelial cells. Pharmacological pepducin- 
based GPR35 blockade markedly reduces tumour size and 
tissue levels of CXCL-1, VEGF, MMP2 and MMP9. GPR35 in 
macrophages is an upstream central coordinator of tissue 
remodelling and tumour- promotion, creating a tumour- 
permissive environment.
How might it impact on clinical practice in the foreseeable 
future?
 ► Anti- VEGF antibodies are approved in cancer therapy to 
reduce tumour growth and angiogenesis, anti- IL-8 antibodies 
are in phase 2 clinical trials and have huge promise to slow 
down tumour angiogenesis.
 ► Blocking GPR35 could be very promising in cancer therapy as 
this reduces the release of both, VEGF and IL-8 and reduces 
tumour cell proliferation by inhibiting neoangiogenesis.
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DSS, nor during the three cycles of AOM/DSS was indifferent 
between Gpr35+/+ and Gpr35–/–, and Gpr35fl/fl and Gpr35ΔMΦ 
mice (online supplemental figure 1A–C). Levels of VEGF, 
CXCL-1 and IL-1β were also markedly lower in inflammatory 
AOM/DSS tumours of Gpr35ΔMΦ compared with Gpr35fl/fl mice 
(figure 1G–I). Inflammatory infiltrate was reduced in Gpr35ΔMΦ 
tumours compared with Gpr35fl/fl tumours (online supplemental 
figure 1E). Macrophages and neutrophils express Gpr35, which 
is efficiently deleted in both cell types in Gpr35ΔMΦ mice (online 
supplemental figure 2B). Of note, GPR35 expression extends 
to human peripheral blood- derived neutrophils and monocyte- 
derived macrophages (online supplemental file 2C). Neutro-
phil activation, measured by tissue MPO levels, were similar 
in Gpr35ΔMΦ and Gpr35fl/fl mice after 3 cycles of AOM/DSS, 
suggesting neutrophil GPR35 did not affect neutrophil activa-
tion per se in this context (online supplemental figure 1F). Alto-
gether, this demonstrated that GPR35 in LysM+ myeloid cells 
potently promotes tumour growth in both CRC and CAC, and 
hinted toward an important role of tumour angiogenesis in this 
microenvironmental pathway.
GPR35 deletion in LysM+ myeloid cells reduces angiogenesis
The architecture of blood vessels in AOM/DSS- induced tumours 
of Gpr35fl/fl mice appeared to be different from that in tumours 
of Gpr35ΔMΦ mice. We observed fewer endothelial cells, identi-
fied by CD31, which stretched along the adenomatous crypts 
in Gpr35ΔMΦ mice, whereas in adenomas from Gpr35fl/fl mice, 
the CD31+ neo- vasculature resembled a reticular structure 
(figure 2A). When these tumours were analysed for total numbers 
of CD31+ cells by FACS, fewer CD31+ cells were detected in 
Gpr35ΔMΦ compared with Gpr35fl/fl tumours (figure 2B). Neither 
primary CD31+ murine endothelial cells, nor human umbilical 
vein endothelial cells, human microvascular endothelial cells 
Figure 1 GPR35 increases tumour size and release of proangiogenic cytokines. (A) The area of intestinal adenomas from Apcmin mice either wild- 
type (Gpr35+/+) and globally deficient for GPR35 (Gpr35-/-) (left panel) or from Gpr35+/+ and Gpr35-/- mice exposed to AOM and three cycles of DSS 
(right panel) were compared. N=7 tumours per genotype. (B) CXCL-1, VEGF and IL-1β levels measured in AOM/DSS tumour tissue of Gpr35+/+ and 
Gpr35-/- mice. N=6 tumours per genotype. (C) Mice conditionally deficient for macrophage GPR35 (Gpr35ΔMΦ) were crossed with APCmin mice and 
tumours were counted when the mice reached an age of 16 weeks. N=14 mice per genotype. (D) Gpr35ΔMΦ mice were exposed to AOM and DSS. 
Colon adenomas were counted in Gpr35ΔMΦ mice and in their control Gpr35fl/fl. N=11 to 13 mice per genotype. (E) Representative images showing 
H&E stain of tumours from Gpr35fl/fl and Gpr35ΔMΦ mice. (F) The area of intestinal adenomas from either Gpr35fl/fl; APCmin and Gpr35ΔMΦ; Apcmin mice 
(left panel) or from Gpr35fl/fl and Gpr35ΔMΦ mice exposed to AOM/DSS (right panel) were compared. N=9 tumours per genotype. (G–I) CXCL-1 (G), 
VEGF (H) and IL-1β (I) levels measured in AOM/DSS tumour tissue of Gpr35fl/fl and Gpr35ΔMΦ mice. N=6 tumours per genotype. All data represented 
as mean±SEM. Statistical significance was calculated using Mann- Whitney U after Kruskal- Wallis testing. * p<0.05, ** p<0.01. AOM, azoxymethane; 
APC, Adenomatosis Polyposis Coli; DSS, dextran sodium sulphate; IL-1β, interleukin 1β; n.s., not significant.
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(HMVECs), or the murine endothelial cell lines SVEC40 and 
H2-11 expressed Gpr35 mRNA (online supplemental figure 
2A). We also noticed that adenomas in Gpr35ΔMΦ mice exhib-
ited only sparse staining for CD206, the mannose receptor and 
a marker of ‘M2’ macrophages, compared with dense staining 
in Gpr35fl/fl adenomas (figure 2A). FACS analysis of Gpr35ΔMΦ 
tumours (online supplemental figure 2D) showed significantly 
less CD68+ cells compared with Gpr35fl/fl tumours (figure 2B). 
The number of CD163+ and CD206+ cells also trended lower 
in Gpr35ΔMΦ compared with Gpr35fl/fl tumours (figure 2B). Ly6- 
G+ cell counts were lower in Gpr35ΔMΦ compared with Gpr35fl/
fl tumours, consistent with lower immune cell infiltration (online 
supplemental figure 1E.) Bone- marrow derived Gpr35+/+ 
macrophages stimulated to differentiate into paradigmatic 
‘M0’, ‘M1’ and ‘M2’ phenotypes secreted substantially more 
of the angiogenic mediators VEGF and CXCL-1 compared 
with their Gpr35–/– counterparts (figure 2C,D). Human M0, 
M1 and M2 macrophages, differentiated from induced plurip-
otent stem cells (iPSC), secreted substantially more VEGF and 
CXCL-8 when they were differentiated from iPSCs genetically 
engineered to express the hypermorphic GPR35 T108M risk 
variant,10 compared with those differentiated from their synge-
neic non- risk parent strain (figure 2E,F). This demonstrated 
that GPR35- dependent angiogenic factor release is conserved 
Figure 2 GPR35 deletion in myeloid cells reduces angiogenic potential. (A) Adenomas from Gpr35fl/fl and Gpr35ΔMΦ mice exposed to AOM/DSS 
stained for CD31+ endothelial cells and CD206+ M2 macrophages. N=5 each genotype, representative confocal microscopy. Scale bars 100 µm. (B) 
FACS analyses of CD31+, CD68+, CD163+, CD206+ and Ly- G6+ cells in Gpr35fl/fl and Gpr35ΔMΦ tumour tissue. N=8–12 Gpr35fl/fl tumours from 8 to 
12 mice and N=7 Gpr35ΔMΦ tumours from mice. (C) VEGF levels in M0, M1 and M2 BMDM from Gpr35+/+ and Gpr35-/- mice. N=6 per genotype. (D) 
CXCL-1 levels in M0, M1 and M2 BMDM from Gpr35+/+ and Gpr35-/- mice. N=6 per genotype. (E) VEGF levels in supernatants of M0, M1 and M2 
human iPS cell- derived macrophages. N=6 each genotype. (F) CXCL-8 levels in supernatants of M0, M1 and M2 human iPS cell- derived macrophages. 
N=6 each genotype. * p<0.05, ** p<0.01. AOM/DSS, azoxymethane followed by dextran sodium sulphate; iPS, inducible- pluripotent- stem; n.s., not 
significant; WT, wild type.
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across species, and the human risk variant profoundly enhances 
their secretion. Macrophages involved in repair and (tumour)
angiogenesis are thought to resemble mainly an M2 phenotype. 
We, therefore, pursued endothelial tube formation assays with 
SVECs or H2-11 murine endothelial cells stimulated with super-
natants from Gpr35+/+ and Gpr35–/– M2 macrophages. Condi-
tioned media from Gpr35+/+ M2 macrophages induced SVECs 
to form significantly longer branches, more junctions within 
the tubular network, and a total area of formed tubes signifi-
cantly larger compared with conditioned media from Gpr35–/– 
macrophages (figure 3A). This suggested that GPR35 controls 
the release of angiogenic factors in macrophages that promote 
endothelial tube formation, a prerequisite of neovascularisation. 
Tube formation only occurs in the presence of growth factors 
such as VEGF. Control experiments show that supernatants of 
BMDM contain sufficient amounts of VEGF and potential other 
soluble factors CXCL-1/CXCL-8. Control RPMI media was not 
able to induce tube formation in 2 H-11 cells, which recurred 
on addition of recombinant VEGF (figure 3B). Blocking VEGF 
with an anti- VEGF antibody reduced branch length, number 
of junctions and the total mesh area, indicating the impor-
tance of growth factors released by macrophages (figure 3C). 
Increased branching and mesh formation of 2 H-11 endothelial 
cells (online supplemental figure 3) when exposed to Gpr35+/+ 
compared to Gpr35–/– macrophage supernatants was associated 
with increased phosphorylation at Tyr1175 of the VEGF receptor 
(figure 3E and online supplemental figure 5A). HMVEC exposed 
to supernatants from human T108M M2 macrophages differen-
tiated from iPSCs also exhibited increased branching and mesh 
formation compared with those from their non- risk counterparts 
(figure 3D). These data were consistent with GPR35- dependent 
secretion of factors, including VEGF, from macrophages that act 
on endothelial cells to promote vessel formation.
GPR35 promotes ex vivo endothelial sprouting
On in vitro culture, fibroblasts and macrophages are the first cells 
to migrate out of the aortic ring, setting the stage for the forma-
tion of neovessels. Endothelial cells typically start migrating 
and proliferating on day 2–3, and pericytes eventually surround 
the elongating sprouts.34 35 Here, we tested whether GPR35 
is involved in vascular sprouting in vascular tissue and hence 
subjected aortic rings from wild- type and knock- out mice to an 
aortic sprout assay. Gpr35–/– aortic rings developed markedly 
fewer vessel sprouts compared with Gpr35+/+ rings (figure 4A). 
Addition of exogenous VEGF (30 ng/mL) was required (added 
on day 1), as only very little sprouting was triggered in wild- type 
and knock- out aortic rings in its absence (figure 4A). Removal of 
large parts of the aortic adventitia, which contains macrophages, 
abrogated the difference between Gpr35+/+ and Gpr35–/– aortic 
rings and let overall far fewer sprouts develop compared with 
when the aortic wall was left intact (figure 4B). Vessel sprouting 
from Gpr35ΔMΦ compared with Gpr35fl/fl aortic rings was equally 
profoundly suppressed (figure 4C) as in Gpr35–/– compared with 
Gpr35+/+ aortic rings. This demonstrated that GPR35 on LysM+ 
myeloid cells orchestrated the outgrowth of neovessels.
KYNA, a product of tryptophan catabolism, and the chemo-
kine CXCL-17 have been suggested as ligands of GPR35.36 37 
Recombinant CXCL-17, added to aortic ring cultures, increased 
vessel sprouting in both Gpr35+/+ and Gpr35–/– aortic rings, indi-
cating that CXCL-17 signals in a GPR35- independent manner 
(figure 4E). KYNA did not alter vessel sprouting, suggesting it 
is not involved in GPR35- mediated angiogenesis (figure 4D). 
Addition of a neutralising anti- VEGF monoclonal antibody on 
day 2 of the experiment, that is, after initial exogenous trig-
gering, reduced vessel sprouting in Gpr35+/+ aortic rings to 
levels observed in Gpr35–/– aortic rings, in which sprouting was 
not affected (figure 4F). Moreover, blocking CXCL-1 signalling 
by blocking its receptor CXCR2 with a selective pepducin38 
also reduced vessel sprouting from Gpr35+/+, but not from 
Gpr35–/– aortic rings (figure 3G). This demonstrated that GPR35 
promotes vessel sprouting via VEGF and CXCR2, which tallied 
with higher VEGF and CXCL-1 secretion in tissue and macro-
phages from Gpr35+/+ compared to Gpr35–/– mice.
GPR35 promotes angiogenesis via the sodium-potassium-
pump in macrophages
Reduced Na/K- ATPase ion pumping activity in the absence 
GPR35 elevates intracellular Ca2+ and lowers K+ levels.10 The 
endogenous cardiotonic steroid ouabain achieves a similar 
effect via binding to Na/K- ATPase and retaining it in an inac-
tive (E2P) state.39 Ouabain indeed reduced vessel sprouting in 
Gpr35+/+ aortas to levels observed in Gpr35–/– aortas, whereas 
sprouting was not significantly changed but slightly increased 
in Gpr35–/– aortas (figure 4H). This was precisely phenocopied 
in aortas from Gpr35fl/fl when compared with Gpr35ΔMΦ mice 
(figure 4I), demonstrating vessel sprouting was coordinated by 
GPR35 on myeloid cells in a Na/K- ATPase- dependent manner. 
Among its non- pump functions, Na/K- ATPase acts as a scaf-
fold for Src kinase and is thereby important in signal transduc-
tion.11 40 41 The α1 type Na/K- ATPase forms a complex with the 
Src SH2 and kinase domain and keeps the kinase domain in an 
inactive state.11 A 20- amino acid sequence (pNaKtide) specifi-
cally inhibits Na/K- ATPase- associated Src activation.42 43 Addi-
tion of pNaKtide peptide decreased sprouting in Gpr35+/+ and 
Gpr35fl/fl aortas to levels observed in their respective Gpr35–/– 
and Gpr35ΔMΦ counterparts, in which pNaKtide had no further 
effect (figure 4J,K). When exposing Gpr35+/+ macrophages to 
ouabain, no increase in Src phosphorylation was observed. This 
was unexpected given previously published work in cell lines 
that do not endogenously express GPR35.43 Src phosphoryla-
tion was indeed increased by ouabain in Gpr35–/– macrophages 
(online supplemental figure 4), pointing towards an important 
role of GPR35 determining the Src signalling response on 
pharmacological inhibition of Na/K- ATPase. Altogether this 
demonstrated that GPR35 expressed on myeloid cells within 
the aortic wall promotes vessel sprouting in a manner depen-
dent on Na/K- ATPase- triggered Src activation.
GPR35-deficient tumours produce less MMPs
A link between MMP-9- positive TAMs and endothelial cells 
responding to angiogenic induction has been established.44 
To assess MMP activity, we performed gelatine zymography 
of extracts from tumours arising in the AOM/DSS model. 
Gpr35–/– tumours exhibited much lower gelatinolytic activity 
compared with Gpr35+/+ tumours (figure 5A). Addition of 
4- aminophenylmercuric acetate (APMA), which activates pro- 
MMPs to active zymogens, to tumour extracts did not further 
increase their gelatinolytic activity (figure 5A). This indicated 
that essentially all available MMP activity in tumours is already 
in the active form. Macrophages can release MMPs and tissue 
inhibitors of MMPs. While native supernatants from Gpr35–/– 
or Gpr35+/+ M1 and M2 BMDMs did not exhibit MMP activity 
(data not shown), addition of APMA to supernatants revealed 
substantial activity in Gpr35+/+ and much lower activity in 
Gpr35–/– macrophage supernatants (figure 5B). Ouabain and 
pNaKtide treatment of Gpr35+/+ M2 macrophages reduced 
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Figure 3 GPR35 deletion in macrophages and neutrophils reduces tube formation. (A) Tube formation assay with murine SVEC endothelial cells 
incubated with Gpr35+/+ and Gpr35-/- M2 macrophage supernatants. Branch length, number of junctions and total mesh area were determined using 
ImageJ’s angiogenesis tool. N=18. (B) 2 H-11 control tube formation assays with control RPMI/10%FBS and RPMI/10%FBS containing 30 ng/mL VEGF. 
No macrophage supernatants present. Branch length, number of junctions and total mesh area were determined using the Image J’s angiogenesis 
tool. N=14 C. 2 H-11 tube formation assays with supernatants of wild- type (WT) and knock- out macrophages in the presence of blocking anti- VEGF 
antibody. Branch length, number of junctions and total mesh area were determined using Image J’s angiogenesis tool. N=14. (D) HMVEC tube 
formation assays with human microvascular endothelial cells. Endothelial cells were incubated with supernatants of iPS cell- derived macrophage 
supernatants (WT and T108M risk variant). Branch length, number of junctions and total mesh area were determined using Image J’s angiogenesis 
tool. N=10. (E) VEGF receptor 2 phosphorylation of 2 H-11 cells treated with WT or Gpr35–/– M2 supernatants. All data represented as mean±SEM. 
Statistical significance was calculated using Mann- Whitney U after Kruskal- Wallis testing. HMVEC, human microvascular endothelial cell; iPS, 
inducible- pluripotent- stem; n.s., not significant.
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their supernatants’ MMP activity (figure 5C), whereas it did 
not affect MMP activity in Gpr35–/– supernatants (figure 5C). 
Differences in zymography were detected in gelatine- but not 
casein gels. We, therefore, measured the gelatinases MMP2 
and MMP9 in tumour tissue and supernatants from BMDM. 
Gpr35ΔMΦ tumours contained substantially less MMP2 and 
MMP9 (figure 5D) compared with AOM/DSS- induced 
tumours from Gpr35fl/fl mice. M2 macrophages from Gpr35–
/– mice correspondingly contained less MMP2 and MMP9 
compared with their Gpr35+/+ counterparts (figure 5E). 
Moreover, supernatants from human iPSC- derived M0 and 
M2 macrophages carrying the T108M risk variant contained 
higher amounts of MMP2 compared with those from non- risk 
variant cells, with MMP2 levels in T108M variant M1 macro-
phages levels also trending higher (figure 5F). Altogether, this 
implied that GPR35 controlled via Na/K- ATPase- dependent 
Src activation the level of MMP activity in tumours, with the 
T108M variant yielding highest levels.
GPR35 increases endothelial transmigration of monocytes
Circulating CCR2+ inflammatory monocytes enter the TME, 
proliferate and differentiate into TAMs,45 a process that 
requires endothelial adhesion and transmigration.46 We there-
fore investigated transmigration by studying myeloid cells 
harvested from 5- day bone marrow cultures, at which point 
cells exhibit a monocyte phenotype.47 Mimicking monocyte 
transmigration, we plated endothelial cells onto Transwell 
membranes and used supernatants from Gpr35+/+ or Gpr35–/– 
M2 macrophages as chemoattractant. Gpr35+/+ or Gpr35–/– 
monocytes added to the upper compartment of the chamber 
migrated through the endothelial cell layer towards the macro-
phage supernatants. Compared with Gpr35+/+ monocytes, 
transmigration of Gpr35–/– monocytes was reduced (figure 6A, 
left panel). Fewer Gpr35–/– than Gpr35+/+ monocytes adhered 
to monolayers of H2-11 murine endothelial cells (figure 6A, 
right panel). Hence GPR35 deficiency in monocytes impaired 
Figure 4 Macrophage GPR35 controls vascular sprouting by interacting with the Na/K- ATPase. (A) Aortic rings from Gpr35+/+ or Gpr35–/– mice 
embedded in collagen matrix. Number of sprouts counted daily until day 9 of the experiment. Aortic rings were either embedded in media containing 
30 ng/mL of VEGF (full circles) or left in OptiMEM media without growth factors (open circles) N=9 mice per genotype. (B) Vascular adventitia was 
removed from aortic rings from Gpr35+/+ or Gpr35–/–. Number of sprouts on day 9. N=6 mice per genotype. (C) Aortic rings from wildtype animals 
(Gpr35fl/fl) or mice lacking GPR35 conditionally on their LysM+ cellsGpr35ΔMΦ. N=13 for Gpr35fl/fl and 23 for Gpr35ΔMΦ mice. (D) KYNA (100 µM) 
was added to the aortic rings of Gpr35+/+ or Gpr35–/– mice and vascular sprouts counted on day 9. N=5 mice for each genotype. (E) CXCL-17 (20 ng/
mL) was added to the aortic rings of Gpr35+/+ or Gpr35–/– mice and vascular sprouts counted on day 9. N=6 mice for each genotype. (F) Anti- VEGF 
antibody (100 ng/mL) was added to the aortic rings of Gpr35+/+ or Gpr35–/– mice and vascular sprouts counted on day 9. n=6 for each genotype. (G) 
Blocking CXCR2 pepducin x1/2pal- i3 (3 µM) was added to the aortic rings of Gpr35+/+ or Gpr35–/– mice and vascular sprouts counted on day 9. n=6 
for each genotype. (H, I.) ouabain (100 µM) was added to the aortic rings of Gpr35+/+ or Gpr35–/– mice (H) and to the aortic rings of Gpr35fl/fl and 
Gpr35ΔMΦ mice (I) and vascular sprouts counted on day 9. N=6 for each genotype. (J, K) pNaKtide (1 µM) was added to the aortic rings of Gpr35+/+ or 
Gpr35–/– mice (J) and to the aortic rings of Gpr35fl/fl and Gpr35ΔMΦ mice (K) and vascular sprouts counted on day 9. N=9 for each genotype. All data 
represented as mean±SEM. Statistical significance was calculated using Mann- Whitney U after Kruskal- Wallis testing.* p<0.05, ** p<0.01. n.s., not 
significant.
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their ability to adhere to, and transmigrate through, endo-
thelial cells. In converse experiments, we exposed endothe-
lial cells to supernatants of either Gpr35+/+ or Gpr35–/– M2 
macrophages, and monocytes of either genotype migrated 
towards wild- type macrophage conditioned media. Mono-
cytes adhered less to endothelial cells that were exposed to 
Gpr35–/– M2 macrophage supernatant than to those exposed 
to Gpr35+/+ supernatant (figure 6B right panel). Transmigra-
tion of monocytes through an endothelial monolayer incu-
bated with Gpr35–/– M2 macrophage conditioned media was 
correspondingly reduced when compared with migration 
through endothelial cells exposed Gpr35+/+ supernatants. 
Fewer Gpr35–/– than Gpr35+/+ monocytes migrated through 
monolayers treated with either Gpr35–/– or Gpr35+/+ macro-
phage supernatants (figure 6B, left panel). This demonstrated 
that GPR35 on macrophages controls the release of factors 
that promoted adhesion and transendothelial migration of 
monocytes.
VCAM-1 is a major endothelial cell adhesion molecule that 
facilitates monocyte transmigration from the peripheral blood 
into the surrounding tissue.48 VCAM-1 expression was higher 
in H2-11 endothelial cells exposed to Gpr35+/+ compared with 
Gpr35–/– M2 macrophage supernatants (figure 6C). This increase 
was abrogated when M2 macrophages were treated overnight 
with ouabain or pNaKtide and then washed, prior to collecting 
supernatants over the ensuing 24 hours (figure 6C and online 
supplemental figure 5B). In contrast, ouabain or pNaKtide treat-
ment of Gpr35–/– M2 macrophages did not affect endothelial 
VCAM-1 expression. This demonstrated that increased VCAM-1 
induction on endothelial cells was dependent on GPR35, 
Figure 5 Lack of GPR35 results in reduced MMP levels. (A) MMP levels in Gpr35+/+ and Gpr35–/– adenomas. Tissue extract MMPs were activated 
with APMA. Area under the curve was analysed using image J. N=6 tumours per genotype. (B) MMP levels in M1 and M2 BMDM supernatants from 
Gpr35+/+ and Gpr35–/– mice. Supernatants were APMA- activated. area under the curve was analysed using image J N=9 mice per genotype. (C) MMP 
levels in M2 macrophages pretreated with ouabain (100 µM) or pNaKtide (1 µM). Area under the curve was analysed using image J N=6 mice per 
genotype. (D) Total (inactive zymogen and active enzyme) MMP2 and MMP9 levels in tumour tissue from Gpr35fl/fl and Gpr35ΔMΦ mice. (E) MMP2 
and MMP9 levels from M2 murine BMDM supernatants. (F) Total (inactive zymogen and active enzyme) MMP2 levels from supernatants of human iPS 
cell- derived macrophages. Macrophages were polarised to M0, M1 and M2 macrophages. All data represented as mean±SEM. Statistical significance 
was calculated using Mann- Whitney U after Kruskal- Wallis testing. * p<0.05, ** p<0.01/ APMA, aminophenylmercuric acetate; MMP, matrix- metallo- 
proteinase; n.s., not significant; WT, wild type.
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Na/K- ATPase and Src activity in macrophages. Consistent with 
such GRP35- dependent regulation, VCAM-1 expression in 
tissue was higher in Gpr35fl/fl compared with Gpr35ΔMΦ mice 
(figure 6C). Activation of extracellular signal- regulated kinases 
(ERK) 1 and 2 by VCAM-1 is critical for endothelial activation, 
transmigration and angiogenesis.48 Conditioned media from 
Figure 6 Lack of GPR35 decreases endothelial transmigration. (A) Right panel: Gpr35+/+ and Gpr35–/– monocytes transendothelial migration 
towards conditioned media from Gpr35+/+ and Gpr35–/– M2 macrophages in the lower compartments of migration chambers. Untreated endothelial 
cell monolayer. Left panel: adhesion of Gpr35+/+ and Gpr35–/– monocytes to 2 H-11 murine endothelial cells. Untreated endothelial cell monolayer. 
N=6 mice per genotype. (B) Left panel: transendothelial migration of monocytes through monolayers of 2 H-11 murine endothelial cells exposed 
to conditioned media from Gpr35+/+ and Gpr35–/– M2 macrophages. right panel: adhesion of Gpr35+/+ and Gpr35–/– monocytes to 2 H-11 murine 
endothelial cells treated with conditioned media from Gpr35+/+ and Gpr35–/– M2 macrophages. N=6 mice per genotype. (C) Upper panel: VCAM-
1 expression in 2 H-11 cells treated with conditioned media from Gpr35+/+ and Gpr35–/– M2 macrophages pretreated with control RPMI, ouabain 
(100 µM) or pNaKtide (1 µM). Lower panel: VCAM-1 expression in Gpr35fl/fl and Gpr35ΔMΦ AOM/DSS tumours. (D) ERK1/2 phosphorylation of 2 H-11 
cells treated with conditioned media from Gpr35+/+ and Gpr35–/– M2 macrophages pretreated with control RPMI, ouabain (100 µM) or pNaKtide 
(1 µM). (E) Src and ERK1/2 phosphorylation in Gpr35+/+ and Gpr35–/– AOM/DSS tumours. N=3 tumours per genotype. (F) Numbers of macroscopic 
and microscopic tumours of either g35i2 or vehicle treated mice with AOM/DSS induced tumours. N=8–9 mice/group. (G) AOM/DSS tumour tissue 
from g35i2 or vehicle treated mice probed for Src and ERK1/2 phosphorylation. N=3 tumours per genotype. (H) CXCL-1, VEGF, MMP2, MMP9 and 
inflammatory infiltrate in tumour tissue from g35i2 or vehicle- treated wild- type mice. N=6 per genotype for CXCL-1, VEGF, MMP2 and MMP9 ELISA 
assays, and n=8 for histological assessment of inflammatory cell infiltrate. All data represented as mean±SEM. Statistical significance was calculated 
using Mann- Whitney U after Kruskal- Wallis testing. AOM/DSS, azoxymethane followed by dextran sodium sulphate; n.s., not significant.
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Gpr35–/– M2 macrophages induced less ERK1/2 phosphoryla-
tion in H2-11 endothelial cells compared with Gpr35+/+ super-
natants (figure 6D and online supplemental figure 5C). Similar 
to VCAM-1 expression, elevated ERK1/2 phosphorylation 
in H2-11 endothelial cells exposed to Gpr35+/+ macrophages 
was prevented by pretreatment of macrophages with ouabain 
or pNaKtide (figure 6D). In contrast, endothelial ERK1/2 
phosphorylation was not affected when triggered by superna-
tants of inhibitor- treated Gpr35–/– macrophages (figure 6D). 
Src and ERK1/2 phosphorylation was correspondingly lower 
in Gpr35–/– compared with Gpr35+/+ tumours (figure 6E and 
online supplemental figure 5D). This hence demonstrated 
that GPR35- modulated activation of Na/K- ATPase, and Na/K- -
ATPase- dependent Src activation, in macrophages controlled 
Erk1/2 phosphorylation and VCAM-1 expression on endothelial 
cells via transmissible signals.
Gpr35 blockade with a GPR35 specific pepducin reduces 
tumour size in the AOM/DSS-induced CAC model
We have previously shown that treatment of wild- type mice 
with a GPR35- selective, inhibitory pepducin (g35i2) reduced 
the number of inflammatory colon tumours.10 In the AOM/
DSS model, the number of macroscopically visible tumours 
in g35i2- treated wild- type mice decreased fivefold, whereas 
the number of microscopic tumours decreased only threefold 
(figure 6F). Src Tyr416 phosphorylation in AOM/DSS tumours 
was substantially lower in g35i2- compared with control- 
treated wild- type mice, and was accompanied by reduced 
Thr202/Thr204 phosphorylation of ERK1/2 (figure 6G). 
Furthermore, CXCL-1, VEGF, MMP2 and MMP9 levels as 
well as immune cell infiltration were significantly decreased 
when wildtype mice were treated with the g35i2 compound 
(figure 6H). Altogether this demonstrated that pharmaco-
logical GPR35 blockade reduced tumour size, involving the 
Na/K- ATPase—Src pathway delineated herein.
DISCUSSION
Here, we report that GPR35 on macrophages is a major promoter 
of tumour growth by facilitating tumour neovascularisation. 
We show that this activity is dependent on Na/K- ATPase, and 
Na/K- ATPase- dependent activation of the non- receptor tyro-
sine kinase Src within macrophages. The profound reduction in 
tumour growth observed in both spontaneous and inflammation- 
induced intestinal tumour models on macrophage- selective dele-
tion of Gpr35 identifies a novel major mechanism, and vividly 
highlights the critical role of myeloid cells in tumour develop-
ment.18 We had previously reported that intestinal epithelial cell- 
specific deletion of Gpr35 reduces intestinal tumour incidence 
and reduces epithelial cell proliferation.10 Our discovery here 
adds a major separate tumour- promoting mechanism of GPR35 
that originates from TAMs and neutrophils. The UC/PSC- linked 
T108M polymorphism of GPR35, which is hypermorphic and 
increases Na/K- ATPase pump activity,10 profoundly increases 
the angiogenic mechanisms as we experimentally demonstrate 
in human macrophages differentiated from gene- edited iPSCs.8 
UC is another strong risk factor for the development of CRC.49 
PSC is the autoimmune disease with the highest lifetime risk of 
developing cancer,7 primarily cholangiocellular carcinoma but 
also CRC.7 GPR35 expression has also been linked to gastric 
cancer,50 and its increased expression in tumour tissue has been 
strongly associated with poor prognosis in colon cancer and 
non- small cell lung cancer.51 52
Neoangiogenesis is imperative for tumour growth and progres-
sion. This is therapeutically exploited by VEGF neutralisation 
(eg, bevacizumab in CRC53), and by IL-8/CXCR2 blockade that 
is currently investigated in clinical trials.54 55 The TME, and 
TAMs in particular, play an eminent role in tumour angiogen-
esis.18 TAMs appear to derive from circulating inflammatory 
monocytes that transmigrate into tumour tissue.56 TAMs with 
a predominantly ‘M2- like’ phenotype stimulate angiogenesis 
by releasing angiogenic cytokines such as VEGF and IL-8.18 27 
GPR35 deletion does not affect differentiation into the para-
digmatic ‘M1’ and ‘M2’ macrophage phenotypes in vitro.10 
Tumours in mice with macrophage- specific or germline Gpr35 
deletion are smaller, contain fewer CD31+ endothelial cells 
and CD206+ M2- like TAMs, and exhibit lower expression of 
VEGF and CXCL-1, altogether implying reduced angiogenesis 
as a major component of reduced tumour growth when GPR35 
is absent. Enhanced monocyte endothelial transmigration in 
vitro, and aortic sprout formation ex vivo, further corrobo-
rate the critical role of macrophage GPR35 in coordinating an 
angiogenic response. MMPs, in particular MMP-2, MMP-9 and 
MMP-14,57 facilitate tissue remodelling, a vital process during 
neo- angiogenesis and tumour progression. MMPs are mostly 
produced by TAMs, released into the extracellular space as inac-
tive zymogen, and subsequently cleaved and activated by other 
proteinases.29 MMP-9, for example, directly releases glycocalyx- 
bound VEGF from cell membranes and decreases the amount of 
syndecan-4 which binds and inactivates VEGF.58 The substan-
tially reduced MMP activity in Gpr35–/– tumours corroborates 
a role of this GPCR as an upstream regulator of tumour tissue 
remodelling.
GPR35 forms a complex with Na/K- ATPase and promotes its 
pumping activity, independent of pharmacological or candidate 
physiological ligands.10 Since Na/K- ATPase ascertains electro-
physiologic homoeostasis in a cell, reduced pumping activity in 
GPR35’s absence increases baseline intracellular Ca2+, which is 
maintained via secondary- active transport, to levels otherwise 
only observed on receptor- mediated signalling events.10 Elevated 
Ca2+ in turn affects Ca2+- dependent signalling processes 
broadly.10 59 Intriguingly, our results infer a critical role of macro-
phage Na/K- ATPase pumping activity in (neo)angiogenesis. 
Teleologically, increasing nutrient and oxygen supply via neo- 
angiogenesis via this mechanism fits with the notion that main-
taining the electrochemical gradient is highly energy- intensive. 
Increased angiogenic activity of GPR35- sufficient myeloid cells 
is further dependent on Na/K- ATPase- dependent Src phosphory-
lation. Cardiotonic steroids such as ouabain block Na/K- ATPase 
pump function by keeping the pump in its E2P state,60 and this 
pharmacological inhibition of pumping activity had been linked 
to increased Src phosphorylation.43 In contrast, in macrophages 
expressing GPR35, pNaKtide- inhibitable and hence Na/K- -
ATPase- dependent Src activation is linked to increased pumping 
activity.10 This relationship of increased Na/K- ATPase activity 
with increased Src activation is also evident in the aortic sprout 
assays we report here. This posits interesting questions on the 
structural basis of GPR35- dependent promotion of pumping 
activity and Src activation.
In summary, we identify GPR35 on myeloid cells as 
upstream coordinator of tumour tissue remodelling, rein-
forcing the critical role of TAMs and neutrophils in cancer 
progression. The GPR35–Na/K- ATPase–Src pathway is 
precisely targetable with GPR35- selective pepducins.10 Its 
upstream role in tumour tissue remodelling renders GPR35 
an attractive target, even in cases where tumour cells them-
selves do not express the receptor.
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